PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

AUG 2 1 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL			Application Number	10/535,240						
			Filing Date	December 21, 2005						
			First Named Invent	Neil Joseph ATKIN						
			Art Unit	1733						
(to be used for all correspondence offer initial filing)			Examiner Name							
(to be used for all correspondence after initial filing) Total Number of Pages in This Submission			Attorney Docket Nu	56108/315567						
		ENCL O	SURES (check all that	t apply)						
Fee Transmittal Form Drawing				After Allowance Communication to TC						
		•	related Papers	Appeal Communication to Board						
Fee Attached		_	-related Fapers		of Appeals and Interferences					
Amendment / Reply		etition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)					
After Final	After Final			o Convert to a al Application			Proprietary Information			
Affidavits/declaration(s)			Attorney, Revocation f Correspondence Addr	ess	Status Le	etter				
Extension of Time Request	□ T-	erminal [Disclaimer	Other Enclosure(s) (please identify below):						
Express Abandonment Request		Request for Refund			1. Form PTO/SB/08 (01 sheet)					
		CD, Number of CD(s)			2. 12 publica	tions				
Informátion Disclosure Statement		☐ Landscape Table on CD								
Certified Copy of Priority Document(s)	Rem	arks								
Reply to Missing Parts/										
Incomplete Application										
Reply to Missing Parts under 37 CFR1.52 or 1	.53									
	SIGNATUR	RE OF A	APPLICANT, ATTOR	RNEY, OF	R AGENT					
Firm										
Signature		mi But								
Printed Name Mid		el A. Berte								
Date A-9. 18.		j. 18, z	L006	54,713						
	CER	TIFICA	TE OF TRANSMISS	ION/MAI	LING					
I hereby certify that this corres class mail in an envelope addre 1450 on the date shown below.	essed to: Mail	eing der Stop Am	posited with the United nendment, Commission	States Po er for Pate	ostal Service ents, P.O. Box	with c 145	sufficie 0, Alex	nt postage as first andria, VA 22313-		
Signature	angela) Om	Possi							
Typed or printed name A		Date	8	18	06					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Neil Joseph ATKIN et al.

SERIAL NO.:

10/535,240

Group Art Unit:

1733

FILED:

December 21, 2005

Examiner:

FOR:

ANGIOGENIC MEDICAL CYANOACRYLATE

ADHESIVE

Attorney Docket No.: 56108/315567

Date: 8/18/06

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the enclosed Form PTO/SB/08 are cited for consideration by the Examiner. Copies of the non-U.S. documents and miscellaneous documents are enclosed.

Submission of the references provided in this Information Disclosure is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specially designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

U.S. Patent Application Serial No. 10/535,240

Filed: December 21, 2005

INFORMATION DISCLOSURE STATEMENT

Page 2

This Information Disclosure Statement is being filed pursuant to 37 C.F.R.

1.97(b), before the mailing date of an office action on the merits. Applicants believe that no fee is due for consideration of this paper. However, if a fee is due, the Commissioner is authorized to charge any fee due to Deposit Account No. 11-0855.

Respectfully submitted,

Michael A. Bertelson

Registration No. 54,713

KILPATRICK STOCKTON LLP Suite 2800, 1100 Peachtree Street Atlanta, Georgia 30309-4530

Phone (404) 815-6500

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

bubstitute for form 1449A/PTO Complete if Known 10/535,240 Application Number **INFORMATION DISCLOSURE** Filing Date December 21, 2005 STATEMENT BY APPLICANT Neil Joseph ATKIN First Named Inventor Art Unit 1733 (Use as many sheets as necessary) Examiner Name 41577/315567 Sheet of 1 Attorney Docket Number

			U.S. PATE	NT D	OCUME	NTS			
Examiner	Examiner Cite Document Number		Publication D	Date	Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Whe			Relevant	
Initials * No.1		Number - Kind Code ² (if known)	MM-DD-YY				Passages or Relevant Figures Appear		
		US 4,847,065	07-11-198	07-11-1989		Akimova, et al.	Tigures Appear		
		US 6,117,425	09-12-200	-28-2000		MacPhee et al	* '		
		US 6,152,141	11-28-200			Stevens et al.			
		US 6,214,332	04-10-200			Askill, et al.			
		US 6,224,622	05-01-2001		Kotzev				
		US 6,299,631	10-09-200)1		Shalaby			
		US 6,316,523	11-13-200			Hyon et al.			
		US 6,342,213 01-29-20		2 Barley et al.					
			FOREIG	N PA	TENT D	OCUMENTS			
F	Foreign Patent Docu		ment		Name of Patentee or		Pages, Columns, Lines,		
	Cite No. ¹	Country Code ³ - Number ⁴ - Kind			Date DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
		WO 86/06738			0-1986	Lazar			
		WO 97/16176			9-1997	Sefton, Michael			
		WO 00/67655			6-2000	Scimed Life Systems			
	WO 01/03607 EP 0 295 721			01-18-2001 12-21-1988		Scimed Life Systems, Inc.			
						The President and Fellows of Harvard College			
		WO 03/008003 A1			0-2003	Loma Linda Univ. Med. Ctr.			
		EP 0 530 804 A1 and B1	09-0	3-1992	Shaw, Robert Francis				
	-	GB 2 201 685 A			2 Moskovsky Gosudaraivenny Meditsinsky Inst.				
		N	ON PATENT LI	TERAT	URE DOC	UMENTS			
Examiner Initials *	Cite No.1	the item (book, magazi	ne, journal, se	rial, sy	mposium		nen appropriate), title of , page(s), volume-issue lhed.	T ²	
,		Bohmig, et al., 'Stable prodr heart allograft survival in a fu	ugs of <i>n</i> -butyric Illy allogenic rat	acid: su strain c	ppression ombination	of T cell alloresponses n,' <i>Transplant Immunolo</i>	in vitro and prolongation of ogy, 7:221-227 (1999)		
Chen, et al., 'Tributyrin: A Prodrug of Butyric Acid for Potential Clinical Application in Differentation The Cancer Research, 54:3494-3499 (1994)									
		Goldsmith, et al., 'Lipid Angio	ogenic Factor fro	om Ome	entum, JAI	AA, 252:2034-2036 (19	34)		
		Wilkinson, et al., 'Biosyntheti Biol. Chem 266:16886-1689		Monobi	utyrin, an A	Adipocyte-secreted Lipid	with Angiogenic Activity,' J.		
Company to					Date				
Examiner Signature					Consid	lered			

AUG 2 1 2006